Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525217 | 0.91 | PDE3A (0.45) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL4665028 | 0.90 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL9868819 | 0.89 | POLA1 (0.44) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL31629449 | 0.88 | PDE4D (0.41) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL4586055 | 0.88 | PDE3A (0.41) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL28758788 | 0.88 | PDE4D (0.42) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL26666720 | 0.88 | LMNA (0.49) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL28309010 | 0.87 | ST6GAL1 (0.38) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL30514303 | 0.87 | LMNA (0.50) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL331769 | 0.85 | LMNA (0.49) | PDE3APDE4DSLC29A1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022123501-A1 | PROTECTED DEOXYDIDEHYDRO-NUCLEOSIDES | VICTORIA LINK LIMITED (NZ) | 2022-06-16 | — | — | WO | claimed |
| EP-0193903-B1 | PRODUCTION OF CYTOSINE NUCLEOSIDES | Takeda Chemical Industries, Ltd. (JP) | 1990-06-13 | — | — | EP | claimed |
| EP-0193903-A2 | Production of cytosine nucleosides | Takeda Chemical Industries, Ltd. (JP) | 1986-09-10 | — | — | EP | claimed |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | SAREPTA THERAPEUTICS, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| CN-116970014-B | Preparation method and application of N-heterocyclic carbene catalyzed selectively acylated nucleoside derivative | 贵州大学 | 2026-02-27 | — | — | CN | disclosed |
| EP-4637812-A1 | HEPATITIS B COMPOSITIONS | GlaxoSmithKline Biologicals S.A. (BE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250171783-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20240415857-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-12-19 | — | — | US | disclosed |
| US-12139709-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | SAREPTA THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-5506337-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1995031459-A1 | MORPHOLINO-SUBUNIT COMBINATORIAL LIBRARY AND METHOD | ANTIVIRALS INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | disclosed |
| EP-0193903-B1 | PRODUCTION OF CYTOSINE NUCLEOSIDES | Takeda Chemical Industries, Ltd. (JP) | 1990-06-13 | — | — | EP | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0260032-A2 | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers | AJINOMOTO CO., INC. (JP) | 1988-03-16 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| EP-0191869-A1 | FISH CALCITONIN DERIVATIVE, PROCESS FOR ITS PREPARATION, AND GENE SYSTEM THEREFOR | HODOGAYA CHEMICAL COMPANY, LIMITED (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415857-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | COL2A1, COL14A1, UPF1 | PDE3A 3199/4885PDE4D 2860/4885SLC29A1 2045/4885 |
| US-12139709-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | GAA, GBA3, GBA1 | PDE3A 2540/4885PDE4D 1999/4885SLC29A1 292/4885 |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | DCLRE1B, OGG1, DCTD | PDE3A 3197/4885PDE4D 1223/4885SLC29A1 206/4885 |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | GAA, GBA3, GBA1 | PDE3A 2540/4885PDE4D 1999/4885SLC29A1 292/4885 |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | PDE3A 3191/4885PDE4D 2835/4885SLC29A1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.